Silvia Panigone

Dr. Panigone is a Managing Director of Outcome Capital based in Europe. With over 25 years of public and private life science company experience, she brings a unique combination of scientific, operational and transactional expertise. She has an extensive track record of financing, M&A transactions and participation in the listing of companies.

Dr. Panigone has broad experience across the life science value chain, having served in C-level positions in a variety of companies, including NLS Pharmaceutics (NASDAQ:NLSP), Bracco and Quintiles. As Chief Operating Officer at NLS Pharmaceutics, she drove the company’s lead asset through IND and a successful Phase II, which triggered investment to support a pivotal study.

Dr. Panigone was previously a Managing Director at I-Bankers Direct, an equity funding web platform, and an Advisor for I-Bankers Securities group, a US investment banking firm. She formerly served as Investment Director at BSI Healthcapital, a life science focused venture capital firm, and was responsible for venture investments in the merchant division of the Swiss bank BSI (now EGF). Dr. Panigone has served as a Director on the boards of multiple US- and EU-based companies, including GlobeImmune, Visioncare Ophthalmic Technologies, Ikonsys, AlphaVax and SpectAquilar, bringing several to an exit transaction.

Dr. Panigone was a Laboratory Head of the Nanotechnology Lab of the IFOM Institute (FIRC Institute of Molecular Oncology) at the European Institute of Oncology. She also served as Strategic & Business Advisor for the Swiss Institute for Cellular Therapies (SCIT) and is currently serving as a Senior Director at XoVenture, a global network of entrepreneurs in the Life Sciences, and Start-Up Coach for the Swiss government (Innosuisse).